Envoy Medical (NASDAQ:COCH) Director Susan Kantor Purchases 96,150 Shares of Stock

Envoy Medical, Inc. (NASDAQ:COCH) Director Susan Kantor bought 96,150 shares of the company’s stock in a transaction on Thursday, February 12th. The stock was purchased at an average cost of $0.40 per share, for a total transaction of $38,460.00. Following the completion of the transaction, the director directly owned 174,037 shares of the company’s stock, valued at approximately $69,614.80. The trade was a 123.45% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Envoy Medical Stock Up 14.8%

NASDAQ COCH opened at $0.69 on Wednesday. The company has a 50-day moving average price of $0.67 and a 200-day moving average price of $0.89. Envoy Medical, Inc. has a 52 week low of $0.36 and a 52 week high of $1.91. The firm has a market capitalization of $19.83 million, a P/E ratio of -0.49 and a beta of 2.10.

Hedge Funds Weigh In On Envoy Medical

A number of hedge funds have recently modified their holdings of COCH. CIBC Bancorp USA Inc. purchased a new stake in shares of Envoy Medical in the third quarter worth $60,000. Geode Capital Management LLC boosted its holdings in Envoy Medical by 111.3% in the 4th quarter. Geode Capital Management LLC now owns 98,351 shares of the company’s stock worth $65,000 after buying an additional 51,813 shares during the period. Finally, Focus Partners Wealth bought a new position in Envoy Medical in the 1st quarter worth $276,000. 8.59% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

COCH has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Envoy Medical in a research note on Tuesday, January 27th. Wall Street Zen raised Envoy Medical to a “sell” rating in a report on Saturday, November 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $9.50.

About Envoy Medical

Envoy Medical (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company’s lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical’s flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals.